700 US Highway 202/206
Bridgewater, NJ 08807
United States
908 977 9900
https://www.insmed.com
版塊: Healthcare
行業: Biotechnology
全職員工: 912
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Mr. William H. Lewis J.D., M.B.A. | President, CEO & Chairman | 1.29M | 6.48M | 1969 |
Ms. Sara M. Bonstein M.B.A. | Chief Financial Officer | 684.18k | 無 | 1981 |
Mr. Roger Adsett M.B.A. | Chief Operating Officer | 894.7k | 無 | 1969 |
Mr. John Drayton Wise M.B.A. | Chief Commercial Officer | 750k | 無 | 無 |
Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer | 763.62k | 無 | 1964 |
Mr. Brian K. Kaspar Ph.D. | Chief Scientific Officer | 無 | 無 | 1974 |
Eleanor Barisser | Associate Director of Investor Relations | 無 | 無 | 無 |
Mr. Michael Alexander Smith J.D. | Chief Legal Officer & Corporate Secretary | 無 | 無 | 1978 |
Mandy Fahey | Executive Director of Corporate Communications | 無 | 無 | 無 |
Ms. S. Nicole Schaeffer M.B.A. | Chief People Strategy Officer | 660.81k | 1.18M | 1968 |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
截至 2024年3月1日 止,Insmed Incorporated 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中:6;董事會:5;股東權利:9;現金賠償:5。